Rose I. Okonkwo
Renal and bone adverse effects of a tenofovir-based regimen in the treatment of HIV-Infected children: a systematic review.
Okonkwo, Rose I.; Weidmann, Anita E.; Effa, Emmanuel E.
Anita E. Weidmann
Emmanuel E. Effa
Introduction Tenofovir disoproxil fumarate (TDF)-containing regimens in the treatment of HIV-infected children have safety concerns with respect to renal and bone toxicity. Objective The aim of this study was to systematically review and critically appraise the literature relating to the reported renal and bone adverse effects of TDF-based regimens in the treatment of HIV-infected children from 2 to 19 years old. Methods Searches were performed using the Cochrane Central Register of Controlled Trials (CENTRAL), Cumulative Index to Nursing and Allied Health Literature (CINAHL), MEDLINE, Ovid SP, Science Direct and Web of Science databases and platforms. All primary studies involving tenofovir use in HIV-infected children were sought. Studies that involved the use of TDF for pre-and post-exposure prophylaxis, and treatment of chronic hepatitis B virus infection were excluded. Data on study characteristics, participant’s characteristics, therapeutic intervention and adverse effects were extracted using a piloted tool. In addition, pharmacovigilance data from the WHO Adverse Reaction database were included. Results We identified 19 studies that reported the presence of renal and bone adverse effects of TDF and these included a total of 1100 study participants. The reports were in distinctly heterogeneous participant groups. A total of 287 renal and bone adverse effects were reported (250 renal and 37 bone adverse effects). Approximately 238 (21.6 %) participants were affected by these adverse effects. Of these, 15 participants stopped their TDF-containing regimen due to these adverse effects. In addition, the pharmacovigilance data from the WHO Adverse Reaction database reported 101 renal and bone adverse effects for patients whose indication was HIV/AIDS. Conclusion This systematic review summarises the reports of renal and bone adverse effects of a TDF-containing regimen in the treatment of HIV-infected children. Our findings suggest that the benefits of using TDF in children need to be balanced against the potential risk of toxicity.
OKONKWO, R.I., WEIDMANN, A.E. and EFFA, E.E. 2016. Renal and bone adverse effects of a tenofovir-based regimen in the treatment of HIV-Infected children: a systematic review. Drug safety [online], 39(3), pages 209-218. Available from: https://doi.org/10.1007/s40264-015-0371-z
|Journal Article Type||Article|
|Acceptance Date||Dec 21, 2015|
|Online Publication Date||Dec 21, 2015|
|Publication Date||Mar 1, 2016|
|Deposit Date||Apr 6, 2017|
|Publicly Available Date||Apr 6, 2017|
|Peer Reviewed||Peer Reviewed|
|Keywords||Renal and bone toxicity; HIV infected; Children|
OKONKWO 2016 Renal and bone adverse effects
Publisher Licence URL
You might also like
Key stakeholders' experiences with the implementation of medication reviews in community pharmacies: a systematic review.
Presentation / Conference
The role of community pharmacists in immunisation: a national cross-sectional study.